Bristol-Myers Squibb vs Medtronic

Bristol-Myers Squibb (BMY), health care, and Medtronic (MDT), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Medtronic is worth $132.1B on the stock market and Bristol-Myers Squibb $124.7B: Medtronic is valued at 6% more. Bristol-Myers Squibb trades at 13.5 times earnings and Medtronic at 25.4. Over the past year Bristol-Myers Squibb's share price has moved +33.7% and Medtronic's +2.06%.

Key facts

Bristol-Myers Squibb market value
$124.7B
Medtronic market value
$132.1B
Bristol-Myers Squibb P/E
13.5
Medtronic P/E
25.4
Bristol-Myers Squibb revenue
$48.2BFY to 2025-12-31
Medtronic revenue
$36.4BFY to 2026-04-24
Superinvestors holding both
3

Market values as of .

Bristol-Myers Squibb vs Medtronic: every measure side by side
Measure Bristol-Myers Squibb Medtronic
SectorHealth CareHealth Care
Country United States Ireland
Fiscal year ends2025-12-312026-04-24
Size
Market cap$124.7Blower$132.1Bhigher
Revenue$48.2Bhigher$36.4Blower
Earnings$7.1Bhigher$4.8Blower
Employees32,500lower95,000higher
Total assets$90Blower$93Bhigher
Valuation
P/E13.5lower25.4higher
P/S2.6lower3.6higher
P/B5.3—
Dividend yield4.00%—
Profitability
Operating margin—17.8%
Balance sheet
Net assets$18.5Blower$49.5Bhigher
Total liabilities$71.5Bhigher$43Blower
Total debt$45.1Bhigher$28Blower
Cash on hand$10.2Bhigher$1.9Blower
Price change
Today-3.08%lower+0.38%higher
1 year+33.7%higher+2.06%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio (under "Both": Bristol-Myers Squibb / Medtronic). Who owns BMY · Who owns MDT

Further comparisons

Learn

Questions and answers

Which is bigger, Bristol-Myers Squibb or Medtronic?

By market value, Medtronic is the larger: $132.1B against $124.7B for Bristol-Myers Squibb. By revenue in its latest fiscal year, Bristol-Myers Squibb is the larger: $48.2B against $36.4B for Medtronic.

Which has the higher P/E ratio?

Medtronic: 25.4, against 13.5 for Bristol-Myers Squibb. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has more debt?

Bristol-Myers Squibb: $45.1B, against $28B for Medtronic. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Bristol-Myers Squibb and Medtronic?

In their latest 13F filings, Richard Pzena, Mark Boyar and Mairs & Power team hold both.

Cite this page

Funkfolio, “Bristol-Myers Squibb vs Medtronic”, data as of 17 November 2026. https://funkfolio.com/compare/bmy-vs-mdt

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.